Welcome to our dedicated page for Blue Water news (Ticker: BWVI), a resource for investors and traders seeking the latest updates and insights on Blue Water stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Blue Water's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Blue Water's position in the market.
Psycheceutical, a subsidiary of Psycheceutical Bioscience (OTC: BWVI), announced a strategic partnership with Vici Health Sciences on March 15, 2022. This collaboration aims to enhance the development of patented psychedelic pharmaceutical delivery technologies, focusing on drugs like ketamine. Vici Health Sciences will assist in testing and developing formulations, leveraging its expertise and GMP facilities for clinical trial materials. The partnership is expected to expedite the market entry of new psychedelic formulations, addressing various mental health conditions.
Psycheceutical, Inc., a bioscience company, has begun the process to update its OTC Markets profile after being fully acquired by Blue Water Ventures International Inc. (OTCPK: BWVI) on January 20, 2022. The merger makes Psycheceutical a wholly-owned subsidiary of BWVI, which will now focus on developing psychedelic drugs and drug delivery technologies. The company also plans corporate actions including a name and symbol change and aims to enhance the safety and efficacy of psychedelic compounds using patented delivery methods. CEO Chad Harman emphasized the importance of becoming a publicly-listed entity.
Psycheceutical, a biotechnology company specializing in psychedelic medicines, has been fully acquired by Blue Water Ventures International (OTCPK: BWVI). Following this merger, Psycheceutical will operate as a wholly-owned subsidiary of BWVI, which will shift its focus exclusively to psychedelic drug development. In response to the acquisition, Psycheceutical's CEO, Chad Harman, expressed enthusiasm about securing capital for growth and initiating clinical trials for its innovative drug delivery technologies.
Blue Water Ventures International (BWVI) has signed a non-binding letter of intent for the acquisition of Psycheceutical, Inc. Upon completion, Psycheceutical will become the surviving entity, with expected changes to its name and symbol. According to Psycheceutical's CEO, Chad Harman, this acquisition is a pivotal step towards advancing their psychedelic drug delivery technologies. The transaction remains subject to due diligence, negotiation, and board approval, and there are no guarantees it will close as planned.
Blue Water Ventures International (OTCPK: BWVI) reported significant progress in its summer recovery project at the SB Pulaski site off North Carolina. The team recovered over 100 silver coins and 32 gold coins, all US minted from the early 1830s, which are now undergoing conservation and grading. President Keith Webb expressed pride in the crew's efforts, marking this as a successful start to the season. The recovery operations are set to continue as weather permits. Additionally, the Blue Water Rose crew collaborated with Expedition Unknown for coverage of their recovery efforts.
Summary not available.
Blue Water Ventures International (OTCPK:BWVI) and Endurance Exploration Group (OTC:EXPL) have extended their Pulaski Joint Venture to the end of 2022. This extension will facilitate further recovery operations at the Pulaski shipwreck site, which has already yielded over 500 artifacts, including coins and silverware. The venture also plans to conduct an updated survey of the SS North Carolina wreck site. The company is focusing on archaeological recoveries of historic shipwrecks and expanding into deep-water salvage.